glp 1 medication side effects long term Your guide to GLP-1 It's Not an Overdose: The

Considering GLP-1 medication for weight or diabetes management

1. Semaglutide (GLP-1)

Costs of prescription drug coverage in the FEHB program rose from just under $10 billion in 2019 to about $14 billion in 2024, with a main driver being a

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

We performed a series of PubMed, Medline and Embase databases systemic searches